83 related articles for article (PubMed ID: 7779141)
1. General pharmacology of the putative cognition enhancer linopirdine.
Flagmeyer I; Gebert I; van der Staay FJ
Arzneimittelforschung; 1995 Apr; 45(4):456-9. PubMed ID: 7779141
[TBL] [Abstract][Full Text] [Related]
2. Selectivity of linopirdine (DuP 996), a neurotransmitter release enhancer, in blocking voltage-dependent and calcium-activated potassium currents in hippocampal neurons.
Schnee ME; Brown BS
J Pharmacol Exp Ther; 1998 Aug; 286(2):709-17. PubMed ID: 9694925
[TBL] [Abstract][Full Text] [Related]
3. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
4. Studies on the role of K+, Cl- and Na+ ion permeabilities in the acetylcholine release enhancing effects of linopirdine (DuP 996) in rat cortical slices.
Maciag CM; Logue AR; Tinker WJ; Saydoff JA; Tam SW; Zaczek R
J Pharmacol Exp Ther; 1994 Nov; 271(2):891-7. PubMed ID: 7965810
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
[TBL] [Abstract][Full Text] [Related]
6. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
Kurumiya S; Miura Y; Nakatsuji K; Dodo M; Hori M; Ito T
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
[TBL] [Abstract][Full Text] [Related]
7. Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neurotransmission.
Fontana DJ; Inouye GT; Johnson RM
Pharmacol Biochem Behav; 1994 Dec; 49(4):1075-82. PubMed ID: 7886078
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
[TBL] [Abstract][Full Text] [Related]
9. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
10. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.
Furuta S; Shimada O; Doi N; Ukai K; Nakagawa T; Watanabe J; Imaizumi M
Arzneimittelforschung; 2004; 54(12):868-80. PubMed ID: 15646371
[TBL] [Abstract][Full Text] [Related]
11. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
[TBL] [Abstract][Full Text] [Related]
12. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.
Zaczek R; Chorvat RJ; Saye JA; Pierdomenico ME; Maciag CM; Logue AR; Fisher BN; Rominger DH; Earl RA
J Pharmacol Exp Ther; 1998 May; 285(2):724-30. PubMed ID: 9580619
[TBL] [Abstract][Full Text] [Related]
13. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
[TBL] [Abstract][Full Text] [Related]
15. On the mechanism of antidepressant-like action of berberine chloride.
Kulkarni SK; Dhir A
Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
[TBL] [Abstract][Full Text] [Related]
16. Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine.
Diamond S; Rakestraw D; O'Neil J; Lam GN; Christ DD
Drug Metab Dispos; 1994; 22(1):65-73. PubMed ID: 8149892
[TBL] [Abstract][Full Text] [Related]
17. Central action of insect neuropeptide, periplanetin CC-1, in mice.
Sieklucka-Dziuba M; Morawska D; Lombarska-Sliwińska D; Konopińska D; Kleinrok Z
Pol J Pharmacol; 1997; 49(1):43-8. PubMed ID: 9431551
[TBL] [Abstract][Full Text] [Related]
18. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
Bartoszyk GD; Harting J; Minck KO
J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
[TBL] [Abstract][Full Text] [Related]
19. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
Atack JR; Bayley PJ; Seabrook GR; Wafford KA; McKernan RM; Dawson GR
Neuropharmacology; 2006 Nov; 51(6):1023-9. PubMed ID: 17046030
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of a new fluoroquinolone on the central nervous system in rodents.
Guiol C; Ledoussal C; Surgé JM
Arzneimittelforschung; 1993 Jan; 43(1):56-60. PubMed ID: 8447850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
